Aerometrex Delivers Strong Subscription Revenue Growth in 1H25
Aerometrex posts 14.8% growth in MetroMap revenue and 67.5% rise in 3D revenue, with a focus on profitabilit
Osteopore (ASX: OSX) Investor Presentation – March 2025
Osteopore (ASX: OSX) pioneers 3D-printed bioresorbable scaffolds for bone regeneration, revolutionizing global healthcare.
ASX Announcement, Chimeric Therapeutics to Undertake Entitlement Offer
Chimeric announces a $3.2M Entitlement Offer to fund CHM CDH17 trials, advancing cell therapy for cancer treatment.